Intuitive Surgical Stock Is Trading at Multi-Year Lows: Is It a Bargain Buy?

The market is pricing ISRG as if the current mix headwinds are structural and company-wide, but the mechanism is narrower: bariatrics is the visible pressure point, while the bigger variable is whether procedure volumes stay resilient across the rest of the elective stack. If the installed base keeps growing and recurring instrument utilization scales with it, the stock’s de-rating can reverse without needing a heroic growth re-acceleration.

The more important second-order risk is not GLP-1s alone; it is any broad weakening in elective procedure demand if ACA subsidy expiration reduces coverage elasticity. That would hit hospitals, ambulatory surgery centers, and disposable-heavy medtech more broadly, with a lag of 1-2 quarters, and would matter more than bariatric mix in a downside case. Falsifier to the bearish narrative: sustained low-teens procedure growth and no deterioration in system placements or procedure mix on the next two earnings prints.

Contrarian view: consensus may be overestimating how persistent the GLP-1 drag is and underestimating the moat effect of a large installed base. At roughly low-30s forward earnings, ISRG is no longer priced for perfection; if growth stays mid-teens, multiple expansion is plausible over 6-18 months. But timing is poor for an outright chase because the near-term catalysts are mostly negative/uncertain, not positive.